James Parkinson, a general practitioner in London, describes six cases of "the shaking palsy" in an early example of defining a neurological condition on the basis of its symptoms. His description of the symptoms and of disease progression (as shown in an illustration from 1886, pictured) remain largely valid today, except for his claim of no cognitive impairment.
Working with Alois Alzheimer in Germany, neurologist Frederic Lewy uses newly developed staining techniques on post-mortem brains of patients who had Parkinson's disease.
Inside various groups of subcortical neurons, Lewy finds distinctive protein aggregates (pictured) that will later be named after him. Lewy also finds variability in the occurrence of these aggregates: a few parkinsonian brains lack them, whereas some healthy brains contain them. This starts a debate, that continues to the present day, about the precise relationship between Lewy bodies and Parkinson's disease.
1919
Neuropathologist Konstantin Tretiakoff suggests that the loss of neurons from the brain's substantia nigra is the pathological hallmark of both Parkinson's disease and post-encephalitic parkinsonism, a similar condition that can occur in people after a viral infection. But other researchers believe that Parkinson's pathology takes root in a different part of the brain called the striatum. It takes decades for Tretiakoff 's hypothesis to be accepted.
1961
In a bid to treat Parkinson's by restoring dopamine levels, Hornykiewicz and Walther Birkmayer, also at the University of Vienna, give patients the dopamine precursor levodopa. Within hours, immobile patients can move, and the effects last up to a day. The drug is also successful in people with post-encephalitic parkinsonism (told in the book and film Awakenings, pictured) and is approved in 1970. Other dopaminebased therapies have since been developed, but levodopa is the gold standard for relieving the motor symptoms of Parkinson's. Oleh Hornykiewicz and Herbert Ehringer at the University of Vienna investigate dopamine levels in the post-mortem brains of two people who had Parkinson's and four who had post-encephalitic parkinsonism. In all six, dopamine levels in the striatum are lower than in unaffected brains. A few years later, researchers find that the striatum's dopamine comes from neurons projecting from the substantia nigra. 
QUOTES FROM THE PAPERS

1987
Neurosurgeon Alim Louis Benabid at Grenoble University in France finds that electrical stimulation of part of the brain's thalamus relieves the motor symptoms of Parkinson's disease (see page S10). Deep brain stimulation becomes popular as a treatment for patients who do not respond to levodopa.
JUNE 1997 AUGUST 1997
Neurobiologists Michel Goedert and Maria Grazia Spillantini are studying α-synuclein at the University of Cambridge, UK, when Polymeropoulus's work comes out. They are intrigued by the Parkinson's connection and devise a study that reveals that the elusive primary constituent of Lewy bodies is α-synuclein.
2003
A group led by neuroanatomist Heiko Braak at Goethe University in Frankfurt, Germany, charts the development of Parkinson's pathology. Braak's team proposes a six-stage process in which lesions and protein aggregates spread through the brain; some of these stages occur before motor symptoms and cell loss. The details are still debated, but 'Braak staging' provides a useful framework for describing the progression of Parkinson's.
2008
Groups from Rush University in Chicago, Illinois, and Lund, Sweden, find that fetal neurons previously transplanted into the brains of people with Parkinson's to restore dopamine production develop Lewy-body-like structures. This suggests that the disease can invade young, healthy tissue. New hypotheses arise, including one suggesting that misfolded α-synuclein can spread from cell to cell, much like infectious misfolded proteins called prions (see page S13).
TO PRESENT DAY
Drugs that halt or slow the progression of Parkinson's disease continue to elude researchers. The NINDS Exploratory Trials in Parkinson Disease Investigators report the latest disappointment: creatine monohydrate. New treatments, some based on genetic insights, are being developed. But James Parkinson's 1817 hope "that some remedial process may ere long be discovered, by which … the progress of the disease may be stopped" remains to be realized. 
